



CrossMark

## Vaccination of Hepatitis A; To Do or Not to Do?

Seyed Farshad Allameh<sup>1,\*</sup>, Morteza Daraie<sup>1</sup>, Reza Taslimi<sup>1</sup>, Nader Roshan<sup>1</sup>,  
Najmeh Aletaha<sup>1</sup>, Mohsen Nasiri Toosi<sup>1</sup>

1. Tehran University of Medical Sciences, Gastrointestinal Ward, Imam Hospital, Tehran, Iran

Please cite this paper as:

Allameh SF, Daraie M, Taslimi R, Roshan N, Aletaha N, Nasiri Toosi M. Vaccination of Hepatitis A; To Do or Not to Do? *Middle East J Dig Dis* 2017;9:246-247. doi: 10.15171/mejdd.2017.83.

This letter was written because of the high incidence of acute hepatitis A in our hospital in this period of time. In December 2016 and January 2017, eight patients with acute hepatitis A were admitted to Gastroenterology Ward of Imam Hospital. Some of them had acute liver failure and fulminant hepatitis.

Fulminant hepatic failure is a rare complication of hepatitis A and it occurs in about 1% of the patients.<sup>1,2</sup> It was previously showed that the severity of hepatitis A was related to age.<sup>3</sup> Acute hepatitis A in adulthood is more severe than in childhood.

In our country there is not routine vaccination program for hepatitis A virus. But because of improving the socioeconomic situation in Iran there are significant number of uninfected adult persons. In this circumstance, sometimes that we have crowded population like religious ritual, outbreak of hepatitis A can occur.<sup>4-6</sup> Because of the older age of patients the prognosis of hepatitis become worsen.

The number of patients with acute hepatitis A in our ward surprisingly elevated in this 2-month period. Almost all of these patients participated in the crowded places. Other viral hepatitis and other causes of acute hepatitis were ruled out. The demographic data and also the lab data of the patients are shown in table 1.

The main purpose of this letter is to investigate about the vaccination of hepatitis A. We think that the Ministry of Health and WHO should evaluate the incidence and also the severity of acute hepatitis A in the whole part of the country especially in adult patients. After evaluation of the cost effectiveness of hepatitis A vaccination revising the vaccination policy should be done especially for high risk adult persons. There are some cost effectiveness studies in the medical literatures.<sup>7</sup> These studies have good guide for this evaluation. An important group of these high risk people for hepatitis A is the pilgrims of Karbala in Arbæen of Imam Hussein, because many people participate in this ritual from many nationalities.

**\* Corresponding Author:**

Seyed Farshad Allameh, MD  
Imam Hospital, Keshavarz Blv, Tehran,  
Iran.  
Telefax: + 98 21 66939922  
Email: allamehfarshad@gmail.com

Received: 06 Jul. 2017

Accepted: 03 Sep. 2017

### CONFLICT OF INTEREST

The authors declare no conflict of interest related to this work.

**Table 1: Demographic and lab data of the patients with acute hepatitis A**

Patient	Bilirubin (T-D) mg/dl	ALP u/l	ALT u/l	AST u/l	INR	Consciousness	Age	Sex
1	6.7-3.7	450	291	150	1	normal	35	male
2	9.9-5.7	325	2788	1031	1.4	normal	27	female
3	13-7.8	435	3000	1141	3.6	decreased	20	male
4	8.7-5.6	275	4841	3531	1.4	normal	24	male
5	8.7-7.2	802	1694	947	1.2	normal	26	female
6	17.3-13.2	350	207	128	1	normal	34	male
7	17.5-8.5	435	1941	1245	1.9	decreased	29	male
8	16.3-10.2	533	1261	279	1.8	normal	28	female

ALP: Alkaline Phosphatase, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase

## REFERENCES

1. Lee HW, Chang DY, Moon HJ, Chang HY, Shin EC, Lee JS, et al. Clinical Factors and Viral Load Influencing Severity of Acute Hepatitis A. *PLoS One* 2015;**10**:e0130728. doi: 10.1371/journal.pone.0130728.
2. Kim JI, Kim YS, Jung YK, Kwon OS, Kim YS, Ku YS, et al. Factors influencing the severity of acute viral hepatitis A. *Korean J Hepatol* 2010;**16**:295-300. doi: 10.3350/kjhep.2010.16.3.295.
3. Lednar WM, Lemon SM, Kirkpatrick JW, Redfield RR, Fields ML, Kelley PW. Frequency of illness associated with epidemic hepatitis A virus infections in adults. *Am J Epidemiol* 1985;**122**:226-33. doi: 10.1093/oxfordjournals.aje.a114093.
4. Farajzadegan Z, Ghaffari Hoseini SH, Kelishadi R, Jamshidi F, Nokhodian Z, Noori R, et al. Systematic review and meta-analysis on the age-specific seroprevalence of hepatitis A in Iran. *J Res Med Sci* 2014;**19**:S56-S63.
5. Mostafavi N, Kelishadi R, Kazemi E, Ataei B, Yaran M, Motlagh ME, et al. Comparison of the Prevalence and Risk Factors of Hepatitis A in 10 to 18-Year-Old Adolescents of Sixteen Iranian Provinces: The CASPIAN-III Study. *Hepat Mon* 2016;**16**:e36437. doi: 10.5812/hepatmon.36437.
6. Karimi A, Mortazaei S, Morad MT. High Prevalence of Symptomatic Hepatitis A Infection in Rural Area of Chaharmahal VA Bakhtiari Province, Iran. *J Clin Diagn Res* 2015;**9**:DC01-DC03. doi: 10.7860/JCDR/2015/9798.5515.
7. Suwantika AA, Beutels Ph, Postma MJ. Cost-effectiveness of hepatitis A vaccination in Indonesia. *Hum Vaccin Immunother* 2014;**10**:2342-349. doi:10.4161/hv.29353.